Devicare, one of the leading biotechnology companies in urology in Spain, presents Canoxidin® to the market; a first-in-class oral treatment that will allow all Spanish urologists to reduce the risk of calcification of urological devices (bladder catheters, ureteral catheters or nephrostomy tubes) by up to 8 times according to the results of Torrecilla et al, 2020 published in BMC Urology.

This project sees the light after a long path of development and clinical research in which to date more than 10 national reference hospitals have participated, has involved more than 20 urologists, and has obtained results of clinical interest that have been presented in more than 15 international scientific congresses and published in up to 3 journals with high impact factor.

"At Devicare we are aware of how important it is for the urologist and his patient to prevent urological devices from calcifying. For this reason we believe that Canoxidin® will revolutionize the way to treat all patients who are in this situation" says Marc Sendra, Product Manager of Devicare.

According to Rosendo Garganta, CEO of Devicare: "Canoxidin® is another step in our commitment to urology to research, develop and bring to the market innovative products that can cover unmet medical needs. The development of Canoxidin® is especially relevant in this commitment because it is the result of the collaboration of many Spanish urologists led by Dr. Carlos Torrecilla from the Hospital de Bellvitge, and represents an international disruption in the treatment of patients with urological devices.”